Life Biosciences Prepares for 2026 Human Trials of Anti-Aging Gene Therapy
【Abstract】: Boston-based Life Biosciences, co-founded by Harvard's Dr. David Sinclair, is preparing to conduct groundbreaking human clinical trials in 2026 for an epigenetic cellular reprogramming therapy. The treatment modifies chemical tags on DNA to rewind the cellular clock and restore tissue function without altering the cell's core identity, initially targeting age-related vision loss and expanding to neurodegenerative diseases.
Business Insight: Epigenetic reprogramming is rapidly transitioning from theoretical science to human clinical applications. For B2B investors and biotech distributors at CMTF, this signals the dawn of a multi-trillion-dollar cellular rejuvenation market. Tracking these early trials is critical for securing future international licensing and distribution rights for cutting-edge longevity therapeutics in the Asia-Pacific region.
【Keywords】: #EpigeneticReprogramming #LongevityTech #AntiAging
【Source Link】: Observer Biotech News (Late 2025 / 2026 Roadmap)
